Signatera™ for Cervical Cancers

Until now, there have been few options to evaluate CCRT response and monitor for recurrence in patients with locally advanced cervical cancer.

Speak with an expert

Powering clinical decisions in cervical cancer

Understand risk

17.5x

Signatera™ -positive immediately post-CRT had a 17.5x higher risk of disease progression.¹

Detect recurrence earlier

3 mo

median lead time – Signatera™ identified 100% of recurrences before imaging.¹

Predict treatment response

100%

of patients with increasing Signatera™ experienced progression while 100% with decreasing/persistently negative Signatera™ experienced clinical benefit and superior PFS.³

Actionable molecular insights across the patient journey

Signatera™ enables early detection of molecular residual disease (MRD) to help you manage your patients with cervical cancers.

A fuller picture may include more than one test

Altera™ comprehensive genomic profiling (CGP)

Altera™ looks at tumor biomarkers and genomic changes that may help inform treatment planning and clinical trial discussions.

View test details

Empower™ hereditary cancer testing

Empower™ is a germline genetic test that looks for inherited cancer risk genes that may be relevant in gynecologic cancers. It may be considered based on your personal history and family history.

View test details

Is Signatera™ for Cervical cancer right for your patients?

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Venchiorruti et al. Journal of Clinical Oncology. 2024;42:3141.

²Kuhn et al. Presented at SGO Winter 2025.

³Recio et al. Presented at SGO 2023.